ReviewClinical cancer research : an official journal of the American Association for Cancer Research2015
Nonviral oncogenic antigens and the inflammatory signals driving early cancer development as targets for cancer immunoprevention.
Review in Clinical cancer research : an official journal of the American Association for Cancer Research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 42 citations in OpenAlex.
- Cancer Antigen 15-3/Mucin 1 Levels in CCTG MA.32: A Breast Cancer Randomized Trial of Metformin vs Placebo.JNCI cancer spectrum · 2021Trial
- ENO1 as an Immunoregulatory Hub in Cancer: Mechanisms and Translational Implications.Biomolecules · 2026Review
- Tumour-reactive plasma cells in antitumour immunity: current insights and future prospects.Immunotherapy advances · 2024Review
- Metformin and Cervical Cancer Risk in Patients with Newly Diagnosed Type 2 Diabetes: A Population-Based Study in Korea.Endocrinology and metabolism (Seoul, Korea) · 2022Article
- Review
- Targets and Strategies for Cancer Immunoprevention.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Development of Peptide-Based Vaccines for Cancer.Journal of oncology · 2022Review
- Cancer Immunoprevention: Current Status and Future Directions.Archivum immunologiae et therapiae experimentalis · 2021Review
- CCDC65 as a new potential tumor suppressor induced by metformin inhibits activation of AKT1 via ubiquitination of ENO1 in gastric cancer.Theranostics · 2021Article
- Cancer Vaccines, Adjuvants, and Delivery Systems.Frontiers in immunology · 2021Review
- Metformin and Biliary Tract Cancer in Patients With Type 2 Diabetes.Frontiers in oncology · 2020Article
- The Role of Adaptor Protein CARD9 in Colitis-Associated Cancer.Molecular therapy oncolytics · 2019Review
- Cancer immunoprevention: from mice to early clinical trials.BMC immunology · 2018Review
- Immunotherapy and Prevention of Pancreatic Cancer.Trends in cancer · 2018Review
- Effects of dexmedetomidine on inflammatory factors, T lymphocyte subsets and expression of NF-κB in peripheral blood mononuclear cells in patients receiving radical surgery of colon carcinoma.Oncology letters · 2018Article
- Emerging trends in the immunotherapy of pancreatic cancer.Cancer letters · 2018Review
- The dawn of vaccines for cancer prevention.Nature reviews. Immunology · 2018Review
- Precision Immuno-Oncology: Prospects of Individualized Immunotherapy for Pancreatic Cancer.Cancers · 2018Review
- Enolase-1 serves as a biomarker of diagnosis and prognosis in hepatocellular carcinoma patients.Cancer management and research · 2018Article
- Association of Metformin Use and Survival Outcome in Women With Cervical Cancer.International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Cancer immunoprevention is an emerging field that holds much promise. Within the past 20 years, prophylactic vaccines have been implemented on the population level for the immunoprevention of carcinomas induced by viruses, specifically hepatitis B virus (HBV) and human papillomavirus (HPV) infection. Armed with the success of prophylactic vaccines that prevent viral-induced tumors, the field must overcome its next hurdle: to develop robust prophylactic vaccines that prevent the remaining >80% of human cancers not induced by viral infection. In this review, we discuss some of the most promising non-virus-associated prophylactic vaccines that target endogenous neoantigens, including the earliest oncogene products, altered mucin 1 (MUC1) and α-enolase (ENO1), all of which produce new targets in the earliest stages of nonviral-induced tumorigenesis. We also highlight a novel attenuated Listeria monocytogenes-based vaccine expressing mutant oncogene Kras(G12D) (LM-Kras) effective in a pancreatic cancer model. A novel chimeric human/rat HER-2 plasmid vaccine (HuRT-DNA vaccine) effective in a breast cancer model is also discussed. In addition to prophylactic vaccine developments, this review highlights the potential use of classic drugs, such as aspirin and metformin, as chemopreventive agents that can potentially be used as adjuvants to enhance the anticancer immunogenicity and efficacy of noninfectious prophylactic vaccines by modulating the inflammatory pathways within the early tumor microenvironment (TME) that propels tumorigenesis. Finally, timing of prophylactic vaccine administration is critical to its immunopreventive efficacy, providing a necessary role of current and emerging biomarkers for cancer screening and early cancer detection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.